A Randomized, Double-blind, Placebo-controlled, Phase III Study (NCT02967692) is being conducted to evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma (63). The gene discussed is BRAF; the disease is melanoma.